Phase I Study of Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy in Patients With Resectable Esophageal Cancer

Study Status

Closed to Enrollment

Study Description

Currently patients with resectable (can be removed by surgery) esophageal cancer will receive chemotherapy before surgery to try to shrink the tumor before it is removed.

The purpose of this study is to determine whether it is safe to give azacitidine before each cycle of chemotherapy to increase the shrinkage of the tumor prior to surgery.
Azacitidine is currently approved by the Food and Drug Administration (FDA) for treatment of myelodysplastic syndrome (MDS). Azacitidine is not approved by the FDA for use in this study and is therefore considered investigational. Because azacitidine has not been given before in combination with epirubicin, oxaliplatin and capecitabine, we will also evaluate the safety and tolerability of azacitidine and find out what dose of azacitidine is safe to give with this chemotherapy.

Disease Status and/or Stage

Resectable Cancer of the Esophagus or Gastroesophageal Junction (GEJ)


Weill Cornell Medical College

Key Eligibility

  • Men and women age 18 to 75
  • Cancer of the esophagus or gastroesophageal junction (GEJ) deemed resectable
  • No prior chemotherapy for esophageal or GEJ cancer
  • Detailed eligibility discussed when you contact the study team

Principal Investigator

Bryan Schneider, MD


Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Erica Bersin
Tel: (646) 962-8232
[email protected]

Top of page